Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medifast (MED) EBT (2016 - 2025)

Medifast's EBT history spans 16 years, with the latest figure at -$6.4 million for Q4 2025.

  • For Q4 2025, EBT fell 600.55% year-over-year to -$6.4 million; the TTM value through Dec 2025 reached -$5.6 million, down 248.84%, while the annual FY2025 figure was -$5.6 million, 248.9% down from the prior year.
  • EBT reached -$6.4 million in Q4 2025 per MED's latest filing, down from -$2.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $61.3 million in Q2 2021 to a low of -$10.6 million in Q2 2024.
  • Average EBT over 5 years is $26.4 million, with a median of $29.5 million recorded in 2022.
  • The largest YoY upside for EBT was 127.0% in 2025 against a maximum downside of 600.55% in 2025.
  • A 5-year view of EBT shows it stood at $46.8 million in 2021, then plummeted by 30.68% to $32.4 million in 2022, then tumbled by 69.75% to $9.8 million in 2023, then plummeted by 86.99% to $1.3 million in 2024, then tumbled by 600.55% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for MED's EBT are -$6.4 million (Q4 2025), -$2.7 million (Q3 2025), and $2.9 million (Q2 2025).